Literature DB >> 10937568

Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension.

N Orzalesi1, L Rossetti, T Invernizzi, A Bottoli, A Autelitano.   

Abstract

PURPOSE: To compare the around-the-clock intraocular pressure (IOP) reduction induced by timolol 0.5%, latanoprost 0.005%, and dorzolamide in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).
METHODS: In this crossover trial, 20 patients with POAG (n = 10) or OHT (n = 10) were treated with timolol, latanoprost, and dorzolamide for 1 month. The treatment sequence was randomized. All patients underwent measurements for four 24-hour tonometric curves: at baseline and after each 1-month period of treatment. The patients were admitted to the hospital, and IOP was measured by two well-trained evaluators masked to treatment assignment. Measurements were taken at 3, 6, and 9 AM and noon and at 3, 6, and 9 PM and midnight by handheld electronic tonometer (TonoPen XL; Bio-Rad, Glendale, CA) with the patient supine and sitting, and a Goldmann applanation tonometer (Haag-Streit, Bern, Switzerland) with the patient sitting at the slit lamp. Systemic blood pressure was recorded at the same times. The between-group differences were tested for significance by means of parametric analysis of variance. The circadian IOP curve of a small group of untreated healthy young subjects was also recorded using the same procedures. To compare the circadian IOP rhythms in the POAG-OHT and control groups, the acrophases for each subject were calculated.
RESULTS: When Goldmann sitting values were considered, all the drugs significantly reduced IOP in comparison with baseline at all times, except for timolol at 3 AM. Latanoprost was more effective in lowering IOP than timolol at 3, 6, and 9 AM (P = 0.03), noon (P = 0.01), 9 PM, and midnight (P = 0.05) and was more effective than dorzolamide at 9 AM, noon (P = 0.03), and 3 and 6 PM (P = 0.04). Timolol was more effective than dorzolamide at 3 PM (P = 0.05), whereas dorzolamide performed better than timolol at midnight and 3 AM (P = 0.05). An ancillary finding of this study was that in the group of healthy subjects, the pattern of IOP curve was different that in patients with eye disease.
CONCLUSIONS: Latanoprost seemed to lead to a fairly uniform circadian reduction in IOP, whereas timolol seemed to be less effective during the nighttime hours. Dorzolamide was less effective than latanoprost but led to a significant reduction in nocturnal IOP. The reason for the difference in the pattern of the IOP curve of healthy subjects is currently unknown and deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937568

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  43 in total

1.  Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension.

Authors:  Norbert Pfeiffer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-16       Impact factor: 3.117

Review 2.  Glaucoma management: relative value and place in therapy of available drug treatments.

Authors:  Deepak Sambhara; Ahmad A Aref
Journal:  Ther Adv Chronic Dis       Date:  2014-01       Impact factor: 5.091

3.  Circadian variations in central corneal thickness and intraocular pressure in patients with glaucoma.

Authors:  P Fogagnolo; L Rossetti; F Mazzolani; N Orzalesi
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

4.  Optimal sampling scheme for estimation of intraocular pressure diurnal curves in glaucoma trials.

Authors:  Chandrasekar Durairaj
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

5.  Changes in trend of newly prescribed anti-glaucoma medications in recent nine years in a Japanese local community.

Authors:  Kenji Kashiwagi
Journal:  Open Ophthalmol J       Date:  2010-04-28

6.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

7.  The additive effect of dorzolamide hydrochloride (Trusopt) and a morning dose of bimatoprost (Lumigan) on intraocular pressure and retrobulbar blood flow in patients with primary open-angle glaucoma.

Authors:  Andrzej Stankiewicz; Joanna Wierzbowska; Anna Siemiatkowska; Beata Fuksinska; Jacek Robaszkiewicz; Arkadiusz Zegadlo; Rita Ehrlich; Brent Siesky; Alon Harris
Journal:  Br J Ophthalmol       Date:  2010-06-16       Impact factor: 4.638

8.  Effects of brinzolamide vs timolol as an adjunctive medication to latanoprost on circadian intraocular pressure control in primary open-angle glaucoma Japanese patients.

Authors:  Makoto Ishikawa; Takeshi Yoshitomi
Journal:  Clin Ophthalmol       Date:  2009-09-07

9.  Role of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.

Authors:  Henny J M Beckers; Jan Sag Schouten; Carroll A B Webers
Journal:  Clin Ophthalmol       Date:  2009-11-02

10.  Recent advances in pharmacotherapy of glaucoma.

Authors:  S K Gupta; Galpalli Niranjan D; S S Agrawal; Sushma Srivastava; Rohit Saxena
Journal:  Indian J Pharmacol       Date:  2008-10       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.